Regencell Bioscience Holdings Limited (RGC) AI Stock Analysis

Regencell Bioscience Holdings Limited is an early-stage Traditional Chinese Medicine (TCM) bioscience company founded in 2014 and based in Causeway Bay, Hong Kong. It operates in the specialty and generic drug manufacturing industry with 10 employees. The firm specializes in researching, developing, and commercializing TCM therapies, focusing primarily on neurocognitive disorders and degenerative conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Regencell aims to combine traditional medical principles with modern scientific approaches to provide holistic treatments for unmet medical needs in neurology and improve overall patient outcomes.

Historically, annual revenue grew at a 2-year compound annual growth rate of 0.6% from $3.13B in FY2016 to $3.16B in FY2018. Over that period, net income moved from $153.4M in FY2016 to $170.4M in FY2017 before declining to $112.3M in FY2018, with gross margin expanding from 61.4% in FY2016 to 96.1% in FY2018. In the trailing twelve months through the latest quarter ended September 30, 2026, the company reported $0 in revenue, a 0.0% operating margin, and an earnings per share figure of -$0.02. Return on equity stood at -128.5% and return on assets was -71.5%.

As of the quarter ended September 30, 2026, Regencell Bioscience held $14.2M in cash and short-term investments against total debt of $295,811, yielding net cash of $13.9M. Total assets stood at $14.7M and shareholders' equity was $13.3M. Liquidity remains supported by a current ratio of 10.77 and a debt-to-equity ratio of 0.02. In FY2026, cash flow deployment included $1.8M spent on share buybacks, while share count changed by 0.4% over five years.

Regencell trades at a market capitalization of $4.76B and an enterprise value of $2.95B. Because trailing twelve-month revenue is $0, standard multiples are unlisted, while the median of its US-listed Healthcare peers trades at a trailing price-to-earnings ratio of 24.6x, forward price-to-earnings of 17.3x, price-to-sales of 4.1x, and EV/EBITDA of 12.0x. Over the past year, the stock returned -46.6%, trailing the S&P 500 return of 16.8%. However, its five-year return of 1855.1% outperforms the S&P 500 five-year return of 83.0%.

There are no analyst rating counts or consensus price targets available for Regencell Bioscience. The company logged 0 EPS beats over the last 4 quarters, having recorded trailing twelve months earnings per share of -$0.02. The company's next earnings date is scheduled for October 30, 2026. Market interest is concentrated internally, with insiders holding 88.4% of shares, institutional ownership at 0.3%, and short interest representing 1.2% of float.

This page is an AI-written research summary of Regencell Bioscience Holdings Limited (RGC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RGC income statement, RGC balance sheet, RGC key metrics, RGC chart. See the RGC stock overview for the latest quote and news.